The Effects of Largazole, a Histone Deacetylase Inhibitor, on Breast Cancer Cell Viability and Metastasis

Histone deacetylase enzymes modify epigenetic characteristics of a genome by removing acetyl groups from histone proteins in chromatin. Histone deacetylase inhibitors work by stopping this activity which can have various results in a cell including apoptosis, cell cycle arrest, differentiation, and migration. The purpose of these experiments was to see how largazole, a histone deacetylase inhibitor, affected cell viability for breast cancer and associated metastatic cell lines in both normoxic and hypoxic conditions. The experiment was completed by setting up two 96-well plates with varying concentrations of largazole and conducting a sulforhodamine viability assay. The specific cell lines used in the experiment were MCF-7, MDA-MB-231, MCF-7 BoM, and MDA-MB-231 BoM. Largazole showed promise in treating triple-negative breast cancer, triple-negative breast cancer metastasis, and estrogen receptor-positive breast cancers